Should Research Ethics Encourage the Production of Cost-Effective Interventions? by Persad, Govind
G. Persad 
Department of Philosophy 
Stanford University 
Stanford, CA 94305-2155 
United States of America 
e-mail: gpersad@alumni.stanford.edu 
 














This project considers whether and how research ethics can contribute to the pro-
vision of cost-effective medical interventions. Clinical research ethics represents 
an underexplored context for the promotion of cost-effectiveness.  In particular, 
although scholars have recently argued that research on less-expensive, less-
effective interventions can be ethical, there has been little or no discussion of 
whether ethical considerations justify curtailing research on more expensive, more 
effective interventions. Yet considering cost-effectiveness at the research stage can 
help ensure that scarce resources such as tissue samples or limited subject popula-
tions are employed where they do the most good; can support parallel efforts by 
providers and insurers to promote cost-effectiveness; and can ensure that research 
has social value and benefits subjects. I discuss and rebut potential objections to 
the consideration of cost-effectiveness in research, including the difficulty of pre-
dicting effectiveness and cost at the research stage, concerns about limitations in 
cost-effectiveness analysis, and worries about overly limiting researchers’ free-
dom. I then consider the advantages and disadvantages of having certain partici-
pants in the research enterprise, including IRBs, advisory committees, sponsors, 
investigators, and subjects, consider cost-effectiveness. The project concludes by 
qualifiedly endorsing the consideration of cost-effectiveness at the research stage. 
While incorporating cost-effectiveness considerations into the ethical evaluation 
of human subjects research will not on its own ensure that the health care system 
realizes cost-effectiveness goals, doing so nonetheless represents an important part 




The moral importance of cost-effectiveness has gained prominence in recent de-
bates about funding medical care. Toby Ord at Oxford, for instance, has argued 
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that there is a moral imperative to use public funding to provide the most cost-
effective interventions, such as preventive care for blindness-causing infections 
like trachoma, rather than more expensive and less cost-effective interventions 
such as guide dogs (Ord 2013). Recent debates over the cost-effectiveness of pro-
grams like the President's Emergency Plan for AIDS Relief (PEPFAR) raise simi-
lar issues (Denny and Emanuel 2008; Emanuel 2012a). 
This project considers whether researching cost-effective interventions is mor-
ally desirable, in contrast to the above arguments, which aim to establish the ethi-
cal importance of providing cost-effective interventions. The view that research 
must have social value in order to be ethical has been prominently defended 
(Emanuel et al. 2000). If social value depends to some extent on cost-
effectiveness, as many believe, then the cost-effectiveness of the intervention be-
ing studied will affect whether research into that intervention is ethical. Research 
will then serve as an institutional gatekeeper in the service of cost-effectiveness, 
just as many have argued that governments, insurers, physicians, and patients 
should work to promote interventions that are cost-effective over those that are 
not. 
I argue for a stance of cautious optimism toward proposals that we consider 
cost-effectiveness when evaluating the ethics of proposed research interventions. 
But I believe that using research ethics to focus research on interventions that are 
cost-effective faces several challenges, most importantly that (1) enforcing cost-
effectiveness norms and (2) predicting either effectiveness or cost are particularly 
difficult at the research stage. Notwithstanding these challenges, research ethics 
constitute an underexplored and potentially important part of the enterprise of 
promoting cost-effectiveness in medicine. 
 
 
2 Cost-Effectiveness in the Development of New Interventions 
Cost-effectiveness analysis in medicine involves comparing the cost of medical in-
terventions, such as pharmaceuticals or devices, against the effectiveness of these 
interventions at producing a desired health outcome. Policymakers and medical 
ethicists have argued that medicine should place a greater emphasis on promoting 
the use of interventions that are cost-effective and discouraging the use of those 
that are not (Emanuel and Fuchs 2008; Orszag and Ellis 2007; Mortimer and Pea-
cock 2012). In circumstances of scarcity, some argue that cost-effectiveness rises 
to the level of a moral imperative: spending a limited pool of money on interven-
tions that are cost-effective enables us to meet more health needs (Denny and 
Emanuel 2008; Ord 2013).  
The provision of medical interventions to patients represents the culmination of 
a multi-stage process involving many actors, and providing many avenues for pol-
icy initiatives to promote cost-effectiveness. Consider, for example, the develop-
ment of lovastatin, the first of the widely prescribed cholesterol-lowering “statin” 
drugs. During the 1970s, basic science research uncovered the biosynthetic path-
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ways by which humans synthesize cholesterol and discovered that compounds 
such as lovastatin inhibit that pathway in fungal models and in preclinical research 
on animals; during the 1980s, lovastatin entered clinical trials; and in 1987, lovas-
tatin was approved by the FDA in the United States (Tobert 2003). Lovastatin was 
quickly accepted by physicians and patients, although some hospitals and insurers 
attempted to restrict its use as a first-line treatment due to its high cost at the time 
(Grabowski 1998; Lederle and Rogers 1990). The story of lovastatin illustrates the 
pathway from the discovery of a promising compound to the provision of a medi-
cal intervention. Although cost-effectiveness considerations only entered the pro-
cess at the hospital or insurer stage in the case of lovastatin, cost-effectiveness 
considerations can and do enter at upstream and downstream stages as well (Table 
1). Downstream, value-based insurance designs could encourage patients to 
choose cost-effective interventions (Thomson et al. 2013). Codes of ethics could 
encourage physicians to provide cost-effective interventions (Emanuel 2012b; 
Weinberger 2011). Upstream, governmental bodies could provide cost-
effectiveness information to insurers, hospitals, and physicians (Wilensky 2006). 
Regulatory agencies could consider an intervention’s cost-effectiveness when de-
ciding whether to approve it for marketing (Paltiel and Pollack 2010). And—as 
this chapter discusses—investigators, sponsors, research ethics committees, and 
research participants could consider an intervention’s cost-effectiveness when de-
ciding whether to begin a clinical trial. 
 
Table 1 Promoting Cost-Effectiveness in the Development of New Interventions 
 













Prioritize funding for cost-effective interventions 
Consider cost-effectiveness when approving trials 
Choose not to pursue research on cost-ineffective 
interventions 
Refuse to participate in trials of interventions that 
are not cost-effective 
Approval for market-
ing 
Regulatory agency (e.g. 
FDA) 
Consider cost-effectiveness in approval process 
Approval for reim-
bursement 
Insurers (e.g. Blue 
Cross, Medicare) 
Reimburse based on cost-effectiveness  
Tax insurance that provides cost-ineffective inter-
ventions 
Use in clinical prac-
tice 
Hospitals, physicians Use formularies 
Use with specific pa-
tients 
Physicians, patients Educate physicians about cost-effective practice 
Adopt value-based insurance that incentivizes pa-




3 Why Promote Cost-Effective Interventions at the Research 
Stage? 
Cost-effectiveness considerations are not altogether foreign to debates over which 
interventions should advance to human testing. However, the most active debates 
about the relevance of cost-effectiveness to human-subject research focus on 
whether cost-effectiveness considerations can expand, rather than limit, the scope 
of allowable research. These debates arise in response to proposed research on 
“less expensive, less effective” interventions: those that promise to be more cost-
effective than the status quo, at some sacrifice to absolute effectiveness. Examples 
include research on less costly methods of lead abatement (Buchanan and Miller 
2006), less costly treatment for multiple sclerosis (Lie 2004), replacement of mul-
tidrug regimens by monotherapy for HIV (Girardi and Angeletti 2013), and less 
costly prevention of maternal-fetal HIV transmission (Wendler et al. 2004).  
That an intervention’s cost-effectiveness can make research that would other-
wise be disallowed ethical, as many of the above authors argue, suggests that cost-
effectiveness has moral significance in the research context. This paper explores 
the heretofore ignored “flip side” of the debate above: whether an intervention’s 
lack of cost-effectiveness can render research into that intervention ethically ob-
jectionable.  
Dividing interventions into the four quadrants of the cost-effectiveness plane 
(Black 1990) helps to illustrate the relationship between the “less expensive, less 
effective” debate and the questions explored in this paper: 
 
 
Table 2 Research Ethics and the Cost-Effectiveness Plane  
 
 More Cost-Effective Less Cost-Effective 
More Absolutely Effective Consensus permission to research Consensus permission to re-
search, challenged here 
Less Absolutely Effective Research permissibility debated Consensus prohibition on re-
search 
 
Research on “dominant” interventions, those promising to be both more cost-
effective and more effective than the status quo, seems clearly acceptable. Re-
search on “dominated” interventions, those less cost-effective and less absolutely 
effective than the status quo, seems clearly unacceptable. The question I explore 
here is whether we can treat research in the northeast quadrant as unproblematic 
while strenuously debating research in the southwest quadrant. Other commenta-
tors have argued for more parallel treatment of the two quadrants at the stage of 
reimbursement and prescribing decisions (Dowie 2004) but this debate has not so 
far extended to research. 
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The numerous policy proposals discussed in Part I—from physician education 
to value-based insurance to cost-effectiveness thresholds for reimbursement—all 
restrict the provision of interventions that are not cost-effective, even though they 
may be absolutely effective. In contrast, the current consensus in research ethics 
seems to treat research into interventions that are more absolutely effective but 
less cost-effective as ethically unproblematic. Yet considering cost-effectiveness 
in research could improve the use of scarce resources, reduce pressure on actors at 
downstream stages, and ensure that research risks to subjects are appropriately 
counterbalanced by social benefits.  
 
3.1 Appropriate Use of Scarce Resources 
First, clinical research—like the provision of interventions—occurs within a 
broader context of scarcity. Some research requires the use of scarce medical re-
sources such as fetal tissue (Woods and Taylor 2008). Other research, such as re-
search on pediatric mood disorders, can only be performed on a limited population 
of subjects, which makes subjects a scarce resource (Frank et al. 2002). Some 
have argued that research subjects are a scarce resource in general (London et al. 
2013; Dresser 2012). Where scarcity exists, priorities must be set, and cost-
effectiveness considerations can help us use limited research resources to produce 
interventions that will help more patients.  
 
3.2 Supporting Downstream Actors 
Second, it may be easier to restrict the provision of treatment on cost-effectiveness 
grounds at earlier stages, such as research or approval, than at later stages, such as 
the physician–patient interaction (Garber 1994). First, those who have invested 
time and money in researching the intervention will have a stake in lobbying 
against cost-effectiveness restrictions, as pharmaceutical manufacturers did after 
the Australian national health insurance agency declined to cover a cervical cancer 
vaccine (Roughead et al. 2008). Second, the further the intervention progresses, 
the more likely it becomes that physicians and patients will come to expect or as-
pire to receive the new intervention; if they treat these expectations or aspirations 
as their new baseline, they will frame the denial of reimbursement as a psycholog-
ically more upsetting loss rather than a mere failure to gain. For instance, it is dif-
ficult to cease provision of a drug that was being provisionally provided while its 
effectiveness was assessed, even if the drug proves ineffective. (While restrictions 
on basic science also have these attractions, the multi-purpose nature of basic sci-
ence means that it will be harder to target restrictions without interfering with re-
search that may yield cost-effective interventions.) 
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3.3 Social Value and Fairness to Research Subjects 
Finally, research involves exposing subjects to risk and harm, which requires 
countervailing benefits. Even at the stage of preclinical research on animals, ethi-
cal guidelines require that the research have social value (Prentice et al. 1992); 
likewise, Emanuel, Grady, and Wendler propose that research on human subjects 
must have social value to be ethical (Emanuel et al. 2000). Some propose that re-
search must not only have social value but also be “responsive” or provide “rea-
sonable availability”—that subjects must have a reasonable prospect of benefiting 
from the intervention being researched (London 2008). 
Cost-effectiveness can help contribute to social value, responsiveness, and rea-
sonable availability. For instance, the expected cost-effectiveness of an HPV vac-
cine regimen can contribute to its social value at the research stage (Lindsey et al. 
2013), and the cost-effectiveness of a hemophilia treatment can establish its rea-
sonable availability to participants (Dimichele 2008). Costly research on gene 
therapy with little evidence of benefit may lack social value (King 2003). Indeed, 
if we accept a reasonable availability or responsiveness requirement, then human 
subjects research on interventions that subject populations will never receive be-
cause later-stage gatekeepers (such as physicians, approval bodies, or insurers) 
will not provide them on cost-effectiveness grounds is unethical. 
Despite the above arguments, there have been few proposals to incorporate 
cost-effectiveness standards into research ethics. One exception is Christine Grady 
and Tito Fojo’s recent criticism of cancer treatments that provide small benefits at 
very high cost, which included a proposal that research be limited on cost-
effectiveness grounds (Fojo and Grady 2009):  
 
Research studies that are powered to detect a survival advantage of 2 months or less should 
only test interventions that can be marketed at a cost of less than $20 000 for a course of 
treatment, which is a monetary value consistent with the cost of one quality adjusted life 
year in patients treated with artificial renal dialysis ($129 090). Similarly, a study designed 
to detect a 4-month advantage can test a therapy that will cost up to $30 000 per patient. 
 
Although Grady and Fojo’s proposal generated a great deal of discussion, very 
little of the discussion focused specifically on their proposed limitation on re-
search. Yet the arguments discussed above give several reasons in support of such 
a limitation. In the next section, I consider some objections to the consideration of 
cost-effectiveness in research. 
 
4 Objections to Considering Cost-Effectiveness at the Research 
Stage 
4.1 The Unpredictability of Effectiveness 
One major objection to the use of cost-effectiveness considerations in research in-
volves the difficulty of predicting, at the clinical trial stage, the effectiveness of 
the intervention being researched. Assessing cost-effectiveness requires an accu-
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rate measure of effectiveness. Two critics of Grady and Fojo’s proposal identified 
this point (Cohen and Looney 2010): 
 
Determining the drug’s clinical value is not something that can or should be decided before 
a drug’s approval, in part because this is what markets do after approval but also because of 
the considerable uncertainty associated with a drug’s real-world effectiveness. 
 
However, even if effectiveness cannot be as precisely predicted at the research 
stage as at later stages, there are ways of assessing effectiveness at the trial stage. 
First, as Grady and Fojo point out, we can use the research study’s power as an 
outer bound on effectiveness: if a study is powered to detect a two-month survival 
difference, then the study cannot show the intervention to be any more effective 
than achieving a two-month increment in survival. Second, trial designs have been 
devised that combine cost-effectiveness predictions with determinations of clinical 
efficacy (Briggs 2000; Drummond and Stoddart 1984). 
 
4.2 The Unpredictability of Cost 
The other dimension of cost-effectiveness measures—cost—is also challenging to 
predict at the clinical trial stage. Cohen and Looney likewise therefore argue that 
“[i]t is inappropriate for pharmaceutical sponsors to impose de facto price controls 
on themselves before a drug’s approval” (Cohen and Looney 2010). While an in-
tervention’s clinical effectiveness is largely determined by human biology, its cost 
is limited only by human choice. The interventions Grady and Fojo claim we 
should not research, like cetuximab, could become highly cost-effective if their 
price was lowered dramatically.  
The measurement of drug costs in cost-effectiveness analysis is controversial. 
The economic ideal is to compare the opportunity cost of the intervention to its 
benefits (Garrison et al. 2010). However, the market price of a medical interven-
tion does not invariably reflect its opportunity cost. For instance, some payments 
to providers reflect the effect of patent rents (Palmer and Raftery 1999) or market 
distortions (Neumann 2009). Estimating costs is particularly difficult at the re-
search stage because so little information is available. 
Notwithstanding these difficulties, some cases exist where opportunity costs 
are easily identifiable even at the research stage, because at least one resource in 
question is absolutely and immediately scarce. Multiple-organ transplants, for in-
stance, arguably constitute a cost-ineffective use of a scarce resource: they use up 
multiple organs to save one life when those organs could have saved two or three 
(Menzel 1994). As such, if we accept the argument against providing multiple-
organ transplants, we should also accept a parallel argument against researching 
such transplants. Likewise, some argued that pharmaceutical companies acted in-
appropriately in promoting the use of antibiotics to treat less severe conditions 
when such use would produce resistance that jeopardizes public health (Kessel-
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heim and Outterson 2010). If this is true, research on the efficacy of antibiotics in 
treating less severe conditions would also be unethical. 
The more difficult questions involve whether and how we should evaluate the 
costs of an intervention at the research stage where absolute scarcity does not ex-
ist. This involves predicting the various costs of the intervention, such as the time 
it will take health professionals to administer it, the wages and profits that will 
need to be paid to those who develop and provide it, and the cost of raw materials 
and technical equipment that will be used in developing and administering it. 
While some of these predictions are technically challenging, empirical and con-
ceptual work on priority setting in research shows promise in helping predict and 
weigh many of the above costs (Bojke et al. 2007; Fleurence and Torgerson 2004; 
Torgerson 2002; Rudan 2012).  
An important issue in prediction is that some costs—in particular wages and 
profits—arise from discretionary choices. Pharmaceutical companies could choose 
to accept lower profits than they do (Schüklenk 2002) or physicians lower in-
comes (Curzer 1992; Menzel 1985). In particular—as Grady and Fojo suggest—
trial sponsors could be required to accept a “cost ceiling” that guarantees that a 
proposed intervention will be made available at a specified price before research is 
allowed to proceed. Such a cost ceiling would be analogous to post-trial access re-
quirements that have been imposed in developing-country trials (Grady 2005). If 
manufacturers refuse to accept a cost ceiling, this undermines their complaint that 
their research is being unjustly limited on cost-effectiveness grounds, since their 
demands are what prevent the interventions from being cost-effective. Manufac-
turers who demand high prices and then complain about limits would be analo-
gous to kidnappers who complain about the hard-heartedness of government re-
fusals to ransom kidnapped individuals (G. Cohen 2010). 
Some might worry that forcing manufacturers to direct research toward cost-
effective interventions will lead to insufficient research into useful medical inter-
ventions. However, current trends suggest an excess of research into costly inter-
ventions with marginal benefit and a deficit of research on cost-effective interven-
tions (Yamey 2002), so encouraging manufacturers to align their research efforts 
with cost-effective goals seems warranted. 
 
4.3 Equity Concerns about Cost-Effectiveness Analysis 
Some have worried that cost-effectiveness analysis is insensitive to concerns about 
justice and interpersonal equity (Brock 2004); others have gone so far as to entire-
ly reject its use on those grounds (Harris 2005). While cost-effectiveness analysis 
has flaws, they cannot justify adopting an approach to research, or to any other 
stage of the process, that entirely ignores cost-effectiveness considerations (Mor-
timer and Peacock 2012). Rather, cost-effectiveness analysis can and should be 
improved to take equity values into account (Menzel 1999).  
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Likewise, some argue that before imposing limits on interventions that are not 
cost-effective, we must first address wasteful spending elsewhere, such as in na-
tional defense (Angell 1985; Daniels 1986; Schrecker 2013). However, while 
wasteful defense spending may mitigate the culpability of medical researchers 
who pursue research on cost-ineffective interventions for the resulting avoidable 
morbidity and mortality, it does not eliminate their culpability, just as criminals’ 
culpability does not eliminate crime victims’ responsibility to avoid injuring inno-
cent bystanders in self-defense (Hurka 2005; McMahan 2011). Indeed, as Harry 
Frankfurt has argued, two actors can both be fully responsible for an outcome 
even when neither of their acts alone would have been sufficient to produce the 
outcome (Frankfurt 1982). 
 
4.4 Freedom of Intellectual Inquiry 
A final objection is that research is a form of intellectual inquiry, and that requir-
ing researchers to consider cost-effectiveness will stifle free inquiry. While this 
objection has force in the context of basic science research, it has much less force 
where human-subject research is concerned. Conducting human-subject research 
is a privilege that comes with conditions and outside oversight, not a purely pri-
vate matter between investigator and subject (Dresser 2012). The use of human 
subjects in research—even with informed consent—requires that the research have 
social value (Emanuel et al. 2000; Joffe and Miller 2008).  
 
 
5 Who Should Ensure that Research Promotes the Development 
of Cost-Effective Interventions? 
If we accept the ethical legitimacy of incorporating cost-effectiveness considera-
tions at the research stage, we face the challenging question of how cost-
effectiveness limitations on research should be implemented. Grady and Fojo, for 
example, do not say who should decide not to pursue clinical trials on interven-
tions that are not cost-effective.  
 
5.1 Research Ethics Committees 
Research ethics committees, such as institutional review boards (IRBs), could em-
ploy cost-effectiveness judgments as part of their evaluation of whether the re-
search in question will have social value. For instance, Berg et al. suggest that it 
might be appropriate to deny approval for research into enhancement technologies 
if such technologies prove to lack cost-effectiveness (Berg et al. 2009). Because 
research ethics committees already have enforcement power and technical exper-
tise, and already review for scientific validity, they seem a natural gatekeeper for 
ensuring that research has social value (London et al. 2013). However, assessing 
10  
social value arguably lies outside the core expertise of ethics review committees 
(Rid and Wendler 2010), and many research ethics committees are already over-
loaded.  
Some may argue that an IRB that refuses to approve research on the basis that 
the interventions produced will not be cost-effective engages in an assessment of 
the “possible long-range effects of applying knowledge gained in the research,” 
which United States law bars IRBs from engaging in (Mano et al. 2006). Howev-
er, the legislative intent of this provision was to prevent IRBs from stifling re-
search on controversial topics, such as correlations between race or gender and 
cognitive ability or criminality (London et al. 2013; Mehlman and Berg 2008). 
Assessments of cost-effectiveness focus on the importance of the knowledge the 
research will provide, which IRBs are permitted to assess, rather than the social 
popularity of the research, which IRBs must not consider.  
Finally, the alignment between libertarian objections to IRB review and liber-
tarian objections to regulation of health care by organizations like the FDA (Ep-
stein 2007) suggests that the same political backlash that has prevented the use of 
cost-effectiveness analysis at other stages (Neumann and Weinstein 2010) may al-
so hamper IRBs in integrating cost-effectiveness norms into research ethics. IRBs 
attempting to limit human subjects research on cost-effectiveness grounds may be 
accused of “mission creep” and censorship, as they have been in other contexts 
(Hyman 2007). IRBs’ remarkable insulation from political intervention (Zywicki 
2007), however, suggests that they may well succeed where other, more elegant 
institutional homes for the promulgation of cost-effectiveness norms have not.  
 
5.2 Research Advisory Committees 
Given IRBs’ local focus and their limited expertise and legal authority, several au-
thors have proposed that research advisory committees (RACs) or other central 
bodies investigate the social implications of research in specific areas, such as be-
havioral genetics, harm reduction, human enhancement, stem cell research, and 
post-trial access to interventions (Baylis and Scott Robert 2006; Fleischman et al. 
2011; Mano et al. 2006). Research on recombinant DNA technologies is currently 
overseen by an RAC (King 2002). 
Would an RAC be an appropriate body to integrate concerns about the cost-
effectiveness of interventions into research ethics? Nancy King recommends that 
RACs be used where “overarching umbrella review and field-wide guidance is 
needed and useful; cross-study analysis of research data for a field is both possible 
and desirable; and public access and education are desired” (King 2002). Several 
of King’s considerations—in particular, the need for field-wide guidance and 
cross-study analysis—do seem applicable to cost-effectiveness. However, cost-
effectiveness considerations are relevant to every clinical trial, while existing and 
proposed RACs focus on a particular area of research, such as human enhance-
ment or gene transfer. As such, requiring all proposals to pass through RAC re-
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view might be unworkably broad; however, a RAC playing a more advisory role 
might be able to collect valuable data on the cost-effectiveness of interventions 
under research that might in turn inform other actors involved in research decision 
making. A RAC with enforcement power might also be appropriate for areas of 
research where cost-effectiveness is uniquely problematic, as Grady and Fojo sug-
gest is true in certain sectors of cancer research. 
 
5.3 Sponsors 
Another possibility is that trial sponsors should employ cost-effectiveness judg-
ments when deciding whether or not to fund a given clinical trial. To the extent 
that trials are privately sponsored, sponsors’ interest in producing profitable drugs 
may seem to militate against this option. However, if cost-effectiveness considera-
tions are relevant at downstream stages, such as formulary inclusion, manufactur-
ers may have an economic interest in ensuring that the interventions they research 
are likely to be adopted in the regulated marketplace. Furthermore, sponsors con-
ducting human subjects research may have ethical obligations other than the max-
imization of profit, which may include obligations to ensure that the research they 
sponsor is socially valuable (Shah 2013; Spinello 1992).  
 
5.4 Investigators 
A fourth possibility is that investigators’ codes of ethics should prohibit work on 
trials that produce interventions that are not cost effective. The possibility of es-
tablishing codes of ethics for investigators or revisiting existing codes of ethics 
has occasionally been discussed as an alternative to IRB review, or as a comple-
ment to such review (Shah 2013). A recent boycott of Abbott Laboratories’ clini-
cal trials motivated by the high costs of Abbott’s HIV drugs seems to reflect some 
physicians’ ethical concern that clinical trials are not leading to the production of 
cost-effective interventions (Dixon and Richwine 2004). 
However, as Shah notes, investigators’ ethical obligations—like sponsors’ ob-
ligations—are under-discussed in the literature (Shah 2013). An investigators’ 
code of ethics that alerts them to the ethical importance of cost-effectiveness, as 
some codes of ethics do for physicians (Emanuel 2012b), could help ensure that 
research promotes the development of cost-effective interventions. For instance, 
Franklin Miller and Steven Joffe’s proposed code of ethics for researchers, which 
regards “promoting socially valuable knowledge about health, disease, and treat-
ment” (emphasis added) as the central aim of human-subject research (Joffe and 
Miller 2008), justifies researchers’ attention to cost-effectiveness to the extent that 
interventions that are not cost-effective are not socially valuable. Likewise, some 
scientific codes of ethics emphasize that scientific research must “enhance the 
public interest or well-being” or otherwise serve the public interest (Resnik and 
Shamoo 2005).  
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5.5 Research Subjects 
Finally, prospective subjects could refuse to participate in trials that will not pro-
duce cost-effective interventions. For instance, breast cancer advocates have ad-
vised prospective subjects to “boycott clinical trials by companies that won’t agree 
to price controls, and which maintain secrecy about their true R&D costs” (Batt 
2000). Likewise, a recent initiative in the United Kingdom has exhorted research 
subjects not to participate in clinical trials that fail to guarantee that their results 
will be made public (Kmietowicz 2013; Limb 2013). Such initiatives might be 
made easier by proposals that trial participants be told about the likely future costs 
of the intervention under study (Barnbaum 2011). 
Efforts by research subjects to promote cost-effectiveness face many of the 
same problems that generally plague workers and consumers attempting to organ-
ize (Lynch 2013). For instance, manufacturers can simply pay subjects enough to 
overcome their objections. Boycotts may end up obstructing research into inter-
ventions that are in fact cost-effective, because subjects are unlikely to have ac-
cess to the most detailed information about future costs or effectiveness. And ex-
isting boycott proposals, though congruent with cost-effectiveness, do not take 
cost-effectiveness as their chief object. Nonetheless, especially if other actors at 
the research stage are unable or unwilling to assist in implementing cost-
effectiveness norms, advocacy and collective action by subjects could play an im-





This article has presented and evaluated the arguments for and against using re-
search ethics to encourage the production of cost-effective interventions. At this 
point, I can offer a tempered endorsement of doing so. Promoting the production 
of cost-effective interventions at the research stage will not, on its own, achieve 
the long-sought goal of cost control in medicine. Nor would it be wise to scale 
back cost control efforts at other stages and use research restrictions as the main 
gatekeeper. The research enterprise is not well suited to be the primary evaluator 
of cost-effectiveness or primary enforcer of cost-effectiveness norms.  
Nonetheless, research can help to share the burden of making cost-effectiveness 
judgments rather than leaving such judgments to downstream actors such as the 
FDA, insurers, hospitals, physicians, or patients. Others have argued that physi-
cians must be among the actors empowered to consider cost-effectiveness, be-
cause relying solely on approval bodies to contain costs will be undermined by 
physicians’ lack of commitment to cost-effectiveness (Ubel and Arnold 1995). 
Similarly, if researchers are not committed to cost-effectiveness, they may gener-
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ate a flood of cost-ineffective interventions that overwhelms downstream actors 
(Rettig 1994). In contrast, judicious adoption of cost-effectiveness norms at the re-
search stage enlists research as part of an “all hands on deck” approach that em-
powers actors at every level of the scientific and regulatory process to promote the 
use of cost-effective interventions (Emanuel and Steinmetz 2013). Existing at-
tempts to limit health care costs have not succeeded in stemming their rise. Pro-
moting cost-effective interventions at the research stage could represent an im-
portant part of an experimental, multi-level approach—like that adopted in the 
United States under the Affordable Care Act (Orszag and Emanuel 2010)—to 
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